Filariasis medical therapy

Jump to navigation Jump to search

Filariasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Filariasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT Scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Filariasis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

slides

Images

American Roentgen Ray Society Images of Filariasis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Filariasis medical therapy

on Filariasis medical therapy

Filariasis medical therapy in the news

Blogs on Filariasis medical therapy

Directions to Hospitals Treating Filariasis

Risk calculators and risk factors for Filariasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

The mainstay treatment for patients with filariasis is albendazole (a broad spectrum anthelmintic) combined with ivermectin.[1] A combination of diethylcarbamazine (DEC) and albendazole is also effective. All of these treatments are microfilaricides; they have no effect on the adult worms.

Medical Therapy

Antimicrobial Regimen

  • 1. Lymphatic filariasis caused by Wuchereria bancrofti, Brugia malayi, Brugia timori
  • Preferred regimen: Diethylcarbamazine 6 mg/kd/day PO tid for 12 days. Single dose of (DEC) has the same long-term effect in decreasing levels of microfilaria in blood as 12-day regimen. If patient is co-infected with onchocerciasis or loiasis DEC is contraindicated. DEC induces reversal of early lymphatic dysfunction in a patient with W.bancrofiti filariasis.[5]
  • Chronic cases:
    • Regular exercise and leg elevation during night increase lymph flow.
    • Physiotherapy may be effective in some cases.
    • Reconstructive surgery involving lymphatic-venous anastomoses have been attempted to improve lymphatic drainage, but the long-term benefit is still unclear.
  • 2. Loa loa filariasis[6]
  • 2.1 Symptomatic loiasis with < 8,000 microfilariae/mL
  • 2.2 Symptomatic loiasis, with < 8,000 microfilariae/mL and failed 2 rounds DEC
  • Preferred regimen: Albendazole 200 mg PO bid for 21 days.
  • 2.3 Symptomatic loiasis, with ≥ 8,000 microfilariae/ml to suppress microfilaremia prior to treatment with DEC
  • Preferred regimen: Albendazole 200 mg PO bid for 21 days.
  • 2.4 Symptomatic loiasis, with ≥ 8,000 microfilariae/mL
  • Preferred regimen: Apheresis followed by Diethylcarbamazine.
  • Note: Apheresis should be performed at an institution with experience in using this therapeutic modality for loiasis.
  • 3. River blindness (onchocerciasis) caused by Onchocerca volvulus
  • Preferred regimen: Ivermectin 150 μg/kg PO single dose, repeated every 6-12 mos until asymptomatic.
  • Alternative regimen: Doxycycline 100 mg PO qd for 6 weeks, alone or followed by Ivermectin 150 μg/kg PO single dose.
  • Note: Do NOT administer Diethylcarbamazine where onchocerciasis is endemic due to increased risk for severe local inflammation in patients with ocular microfilariae.
  • 4. Mansonella ozzardi
  • Preferred regimen: Ivermectin 200 μg/kg PO single dose.
  • Note: Endosymbiotic Wolbachia are essential to filarial growth, development, embryogenesis and survival and represent an additional target for therapy. Doxycycline 100–200 mg PO qd for 6–8 weeks results in loss of Wolbachia and decrease in both micro- and macrofilariae.
  • 5. Mansonella perstans
  • Preferred regimen: Doxycycline 100–200 mg PO qd for 6–8 weeks.
  • 6. Mansonella streptocerca
  • 7. Tropical pulmonary eosinophilia caused by Wuchereria bancrofti

References

  1. U.S. Centers for Disease Control, Lymphatic Filariasis Treatment, retrieved 2008-07-17
  2. "Drugs for Parasitic Infections (Treatment Guidelines from The Medical Letter)".
  3. Taylor MJ, Hoerauf A, Bockarie M (2010). "Lymphatic filariasis and onchocerciasis". Lancet. 376 (9747): 1175–85. doi:10.1016/S0140-6736(10)60586-7. PMID 20739055.
  4. Knopp S, Steinmann P, Hatz C, Keiser J, Utzinger J (2012). "Nematode infections: filariases". Infect Dis Clin North Am. 26 (2): 359–81. doi:10.1016/j.idc.2012.02.005. PMID 22632644.
  5. Moore TA, Reynolds JC, Kenney RT, Johnston W, Nutman TB (1996). "Diethylcarbamazine-induced reversal of early lymphatic dysfunction in a patient with bancroftian filariasis: assessment with use of lymphoscintigraphy". Clin Infect Dis. 23 (5): 1007–11. PMID 8922794.
  6. "Parasites - Loiasis (CDC)".